111 related articles for article (PubMed ID: 12444552)
21. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
22. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice.
Santoro M; Chiappetta G; Cerrato A; Salvatore D; Zhang L; Manzo G; Picone A; Portella G; Santelli G; Vecchio G; Fusco A
Oncogene; 1996 Apr; 12(8):1821-6. PubMed ID: 8622903
[TBL] [Abstract][Full Text] [Related]
23. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes.
Endo T; Kobayashi T
Endocr Relat Cancer; 2013 Dec; 20(6):767-76. PubMed ID: 24014739
[TBL] [Abstract][Full Text] [Related]
24. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.
Russell JP; Powell DJ; Cunnane M; Greco A; Portella G; Santoro M; Fusco A; Rothstein JL
Oncogene; 2000 Nov; 19(50):5729-35. PubMed ID: 11126359
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.
Lanzi C; Cassinelli G; Cuccuru G; Zaffaroni N; Supino R; Vignati S; Zanchi C; Yamamoto M; Zunino F
Cell Mol Life Sci; 2003 Jul; 60(7):1449-59. PubMed ID: 12943231
[TBL] [Abstract][Full Text] [Related]
26. Prevalence, significance, and biological behavior of ret/PTC1 associated papillary thyroid carcinoma.
Cetta F
J Clin Endocrinol Metab; 1997 May; 82(5):1650. PubMed ID: 9141569
[No Abstract] [Full Text] [Related]
27. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma.
Sozzi G; Bongarzone I; Miozzo M; Borrello MG; Blutti MG; Pilotti S; Della Porta G; Pierotti MA
Genes Chromosomes Cancer; 1994 Apr; 9(4):244-50. PubMed ID: 7519046
[TBL] [Abstract][Full Text] [Related]
28. [Oncogenes RET/PTC and mechanisms of their involvement in thyroid cancerogenesis].
Voskoboĭnyk LH
Ukr Biokhim Zh (1999); 2009; 81(6):17-25. PubMed ID: 20387655
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma.
Raouane M; Desmaele D; Gilbert-Sirieix M; Gueutin C; Zouhiri F; Bourgaux C; Lepeltier E; Gref R; Ben Salah R; Clayman G; Massaad-Massade L; Couvreur P
J Med Chem; 2011 Jun; 54(12):4067-76. PubMed ID: 21561161
[TBL] [Abstract][Full Text] [Related]
30. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol.
Ali HM; Maksimenko A; Urbinati G; Chapuis H; Raouane M; Desmaële D; Yasuhiro H; Harashima H; Couvreur P; Massaad-Massade L
Thyroid; 2014 Feb; 24(2):327-38. PubMed ID: 23885719
[TBL] [Abstract][Full Text] [Related]
31. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.
La Perle KM; Jhiang SM; Capen CC
Am J Pathol; 2000 Aug; 157(2):671-7. PubMed ID: 10934169
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative.
Lanzi C; Cassinelli G; Pensa T; Cassinis M; Gambetta RA; Borrello MG; Menta E; Pierotti MA; Zunino F
Int J Cancer; 2000 Feb; 85(3):384-90. PubMed ID: 10652431
[TBL] [Abstract][Full Text] [Related]
33. Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/PTC1 oncogene.
Sagartz JE; Jhiang SM; Tong Q; Capen CC
Lab Invest; 1997 Mar; 76(3):307-18. PubMed ID: 9121114
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.
Bongarzone I; Monzini N; Borrello MG; Carcano C; Ferraresi G; Arighi E; Mondellini P; Della Porta G; Pierotti MA
Mol Cell Biol; 1993 Jan; 13(1):358-66. PubMed ID: 7678053
[TBL] [Abstract][Full Text] [Related]
35. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.
Leone V; Ferraro A; Schepis F; Federico A; Sepe R; Arra C; Langella C; Palma G; De Lorenzo C; Troncone G; Masciullo V; Scambia G; Fusco A; Pallante P
Cancer Lett; 2015 Feb; 357(2):535-41. PubMed ID: 25497869
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
37. [Genetic factors predisposing to the development of papillary thyroid cancer].
Puzianowska-Kuźnicka M; Pietrzak M
Endokrynol Pol; 2005; 56(3):339-45. PubMed ID: 16350729
[TBL] [Abstract][Full Text] [Related]
38. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice.
Chen Y; Li YH; Chen XP; Gong LM; Zhang SP; Chang ZJ; Zhang XF; Fu XY; Liu L
Cancer Res; 2005 Dec; 65(23):10838-46. PubMed ID: 16322230
[TBL] [Abstract][Full Text] [Related]
39. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
Carlomagno F; Vitagliano D; Guida T; Basolo F; Castellone MD; Melillo RM; Fusco A; Santoro M
J Clin Endocrinol Metab; 2003 Apr; 88(4):1897-902. PubMed ID: 12679489
[TBL] [Abstract][Full Text] [Related]
40. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.
Cassinelli G; Favini E; Degl'Innocenti D; Salvi A; De Petro G; Pierotti MA; Zunino F; Borrello MG; Lanzi C
Neoplasia; 2009 Jan; 11(1):10-21. PubMed ID: 19107227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
